BREZTRI breathes new life into COPD management

NCT ID NCT06422676

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked at 200 people with moderate to severe COPD who started taking the triple-combination inhaler BREZTRI. Researchers tracked changes in symptoms and lung function over 24 weeks in routine doctor visits. The goal was to see how the medicine performs outside of strict clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Blagoveshchensk, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Krasnodar, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Rostov-on-Don, Russia

  • Research Site

    Ryazan, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Ufa, Russia

  • Research Site

    Volgograd, Russia

  • Research Site

    Yekaterinburg, Russia